BR112017023788A2 - composições de ácido nucleico?polímero catiônico e processo para a preparação de dita composição - Google Patents
composições de ácido nucleico?polímero catiônico e processo para a preparação de dita composiçãoInfo
- Publication number
- BR112017023788A2 BR112017023788A2 BR112017023788A BR112017023788A BR112017023788A2 BR 112017023788 A2 BR112017023788 A2 BR 112017023788A2 BR 112017023788 A BR112017023788 A BR 112017023788A BR 112017023788 A BR112017023788 A BR 112017023788A BR 112017023788 A2 BR112017023788 A2 BR 112017023788A2
- Authority
- BR
- Brazil
- Prior art keywords
- nucleic acid
- cationic polymer
- preparing
- composition
- polymer compositions
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 229920006317 cationic polymer Polymers 0.000 title abstract 2
- 238000004519 manufacturing process Methods 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0091—Purification or manufacturing processes for gene therapy compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Manufacturing & Machinery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL23864315 | 2015-05-05 | ||
| PCT/IL2016/050477 WO2016178233A1 (en) | 2015-05-05 | 2016-05-05 | Nucleic acid-cationic polymer compositions and methods of making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017023788A2 true BR112017023788A2 (pt) | 2018-10-16 |
Family
ID=56134418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017023788A BR112017023788A2 (pt) | 2015-05-05 | 2016-05-05 | composições de ácido nucleico?polímero catiônico e processo para a preparação de dita composição |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20180154023A1 (enExample) |
| EP (1) | EP3291799A1 (enExample) |
| JP (2) | JP2018515479A (enExample) |
| KR (1) | KR20180015145A (enExample) |
| CN (1) | CN107735079A (enExample) |
| AU (1) | AU2016258326A1 (enExample) |
| BR (1) | BR112017023788A2 (enExample) |
| CA (1) | CA2984879A1 (enExample) |
| IL (1) | IL255254A0 (enExample) |
| MX (1) | MX2017014060A (enExample) |
| PH (1) | PH12017502216A1 (enExample) |
| RU (1) | RU2017140065A (enExample) |
| SG (2) | SG11201708760PA (enExample) |
| WO (1) | WO2016178233A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2018515479A (ja) * | 2015-05-05 | 2018-06-14 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ Ｌｔｄ． | 核酸−カチオン性ポリマー組成物、並びにその作製方法及び使用方法 |
| DE102017003004A1 (de) | 2017-03-23 | 2018-09-27 | Friedrich-Schiller-Universität Jena | Kationische Polymere mit D-Fructose-Substituenten |
| US10849921B2 (en) * | 2017-05-17 | 2020-12-01 | Bioncotech Therapeutics Sl | Pharmaceutical composition comprising particles comprising a complex of a double-stranded polyribonucleotide and a polyalkyleneimine |
| EP3924463A1 (en) | 2019-02-11 | 2021-12-22 | Excellgene SA | Novel eukaryotic cell transfection systems and related methods |
| CN111363761A (zh) * | 2020-03-17 | 2020-07-03 | 苏州吉恒基因科技有限公司 | 利用阳离子多聚体dna复合物促进aav介导的基因表达方法 |
| CA3181339A1 (en) * | 2020-04-27 | 2021-11-04 | Juno Therapeutics, Inc. | Stabilization of polyethyleneimine-deoxyribonucleic acid complex size and activity |
| TW202228727A (zh) * | 2020-10-01 | 2022-08-01 | 德商拜恩迪克公司 | 適用於治療之微脂體ｒｎａ調配物之製備及儲存 |
| WO2022249180A1 (en) | 2021-05-25 | 2022-12-01 | Ramot At Tel-Aviv University Ltd. | Compositions comprising extracellular vesicles and an active agent and uses thereof |
| CN113501889A (zh) * | 2021-07-06 | 2021-10-15 | 郑州大学 | 一种三七多糖阳离子衍生物的制备方法及其应用 |
| CN116549626A (zh) * | 2022-01-27 | 2023-08-08 | 深圳瑞吉生物科技有限公司 | 一种载核酸脂质纳米颗粒冻干制剂及其制备方法与应用 |
| CN114762731B (zh) * | 2022-05-16 | 2024-08-23 | 常州大学 | 一种延长基因药物在温和条件下储存时间的方法 |
| CN116036043A (zh) * | 2023-01-10 | 2023-05-02 | 深圳市乐土生物医药有限公司 | 一种核酸药物制剂、冻干粉及制备方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5116742A (en) | 1986-12-03 | 1992-05-26 | University Patents, Inc. | RNA ribozyme restriction endoribonucleases and methods |
| US4987071A (en) | 1986-12-03 | 1991-01-22 | University Patents, Inc. | RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| FR2722506B1 (fr) | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucleiques, preparation et utilisations |
| US6087164A (en) * | 1997-10-03 | 2000-07-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Methods and compositions for inducing tumor-specific cytotoxicity |
| US20040142474A1 (en) * | 2000-09-14 | 2004-07-22 | Expression Genetics, Inc. | Novel cationic lipopolymer as a biocompatible gene delivery agent |
| WO2007007317A1 (en) | 2005-07-07 | 2007-01-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nucleic acid agents for downregulating h19, and methods of using same |
| JP2009508516A (ja) | 2005-09-22 | 2009-03-05 | イッサム リサーチ ディベロプメント カンパニー オブ ザ ヘブリュー ユニバーシティ オブ エルサレム | 核酸構築物、薬剤組成物、及び癌治療のためのその使用方法 |
| CA2675967A1 (en) | 2007-01-16 | 2008-07-24 | Yissum Research Development Company Of The Hebrew University Of Jerusale M | Nucleic acid constructs and methods for specific silencing of h19 |
| US20090042825A1 (en) * | 2007-08-06 | 2009-02-12 | Majed Matar | Composition, method of preparation & application of concentrated formulations of condensed nucleic acids with a cationic lipopolymer |
| CN101820864A (zh) * | 2007-08-06 | 2010-09-01 | 艾根股份有限公司 | 核酸-脂聚合物组合物 |
| BRPI0818937B8 (pt) | 2007-10-25 | 2021-05-25 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | constructos contendo múltiplos cassetes de expressão para terapia de câncer |
| WO2010028093A2 (en) * | 2008-09-03 | 2010-03-11 | Senesco Technologies, Inc. | Use of a truncated elf-5a1 polynucleotide to induce apoptosis in cancer cells |
| DE102009006606A1 (de) * | 2009-01-29 | 2010-08-05 | Philipps-Universität Marburg | Nicht-virales Transfektionsmittel |
| JP2018515479A (ja) * | 2015-05-05 | 2018-06-14 | イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム リミテッドＹｉｓｓｕｍ Ｒｅｓｅａｒｃｈ Ｄｅｖｅｌｏｐｍｅｎｔ Ｃｏｍｐａｎｙ Ｏｆ Ｔｈｅ Ｈｅｂｒｅｗ Ｕｎｉｖｅｒｓｔｙ Ｏｆ Ｊｅｒｕｓａｌｅｍ Ｌｔｄ． | 核酸−カチオン性ポリマー組成物、並びにその作製方法及び使用方法 |
-
2016
- 2016-05-05 JP JP2017556986A patent/JP2018515479A/ja active Pending
- 2016-05-05 KR KR1020177034664A patent/KR20180015145A/ko not_active Ceased
- 2016-05-05 CN CN201680039770.4A patent/CN107735079A/zh active Pending
- 2016-05-05 RU RU2017140065A patent/RU2017140065A/ru not_active Application Discontinuation
- 2016-05-05 BR BR112017023788A patent/BR112017023788A2/pt not_active Application Discontinuation
- 2016-05-05 CA CA2984879A patent/CA2984879A1/en not_active Abandoned
- 2016-05-05 WO PCT/IL2016/050477 patent/WO2016178233A1/en not_active Ceased
- 2016-05-05 MX MX2017014060A patent/MX2017014060A/es unknown
- 2016-05-05 US US15/571,699 patent/US20180154023A1/en not_active Abandoned
- 2016-05-05 AU AU2016258326A patent/AU2016258326A1/en not_active Abandoned
- 2016-05-05 EP EP16730012.8A patent/EP3291799A1/en not_active Withdrawn
- 2016-05-05 SG SG11201708760PA patent/SG11201708760PA/en unknown
- 2016-05-05 SG SG10201909209R patent/SG10201909209RA/en unknown
-
2017
- 2017-10-25 IL IL255254A patent/IL255254A0/en unknown
- 2017-12-05 PH PH12017502216A patent/PH12017502216A1/en unknown
-
2020
- 2020-01-02 US US16/732,770 patent/US20200138977A1/en not_active Abandoned
-
2021
- 2021-05-07 JP JP2021079039A patent/JP2021130671A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL255254A0 (en) | 2017-12-31 |
| EP3291799A1 (en) | 2018-03-14 |
| US20200138977A1 (en) | 2020-05-07 |
| US20180154023A1 (en) | 2018-06-07 |
| RU2017140065A (ru) | 2019-06-05 |
| KR20180015145A (ko) | 2018-02-12 |
| CN107735079A (zh) | 2018-02-23 |
| MX2017014060A (es) | 2018-07-06 |
| CA2984879A1 (en) | 2016-11-10 |
| JP2021130671A (ja) | 2021-09-09 |
| AU2016258326A1 (en) | 2017-11-23 |
| WO2016178233A1 (en) | 2016-11-10 |
| RU2017140065A3 (enExample) | 2019-09-27 |
| SG11201708760PA (en) | 2017-11-29 |
| PH12017502216A1 (en) | 2018-06-11 |
| JP2018515479A (ja) | 2018-06-14 |
| SG10201909209RA (en) | 2019-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017502216A1 (en) | Nucleic acid-cationic polymer compositions and methods of making and using the same | |
| AR093377A1 (es) | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco | |
| BR112018010585A2 (pt) | composições de betume compreendendo lignina | |
| BR112018067368A2 (pt) | terapia de combinação com anticorpos anti-cd73 | |
| BR112016004023A2 (pt) | Composição, métodos para preparar uma composição e para tratar uma doença, e, composto | |
| AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
| BR112015012987A2 (pt) | composições compreendendo anticorpos anti-cd38 e lenalidomida | |
| CO7240361A2 (es) | Composiciones de arni de serpinc1 y métodos de uso de las mismas | |
| BR112015023752A2 (pt) | complexos multiespecificos monovalentes e multivalentes e seus usos | |
| BR112016017261A8 (pt) | composto, composição farmacêutica, uso de um composto e processo para a fabricação de um composto | |
| MX2017004039A (es) | Fosforamiditas de n-acetilgalactosamina (galnac), conjugados de acido nucleico de las mismas y su uso. | |
| MX2020011415A (es) | Metodos de usar zscan4 para rejuvenecer celulas humanas. | |
| MX387994B (es) | Derivados de pirazol como moduladores del canal de calcio activado por liberacion de calcio. | |
| ECSP14013132A (es) | Anticuerpos anti-psgl-1 y usos de los mismos | |
| BR112016015105A2 (pt) | Conjugados var2csa-droga | |
| BR112015011244A2 (pt) | Análogos de compstatina de ação prolongada, método de fabricação e uso dos mesmos, bem como composição de qualidade farmacêutica | |
| CY1121859T1 (el) | Μεθοδος παρασκευης αναστολεων συνθασης γλυκοζυλοκεραμιδης | |
| BR112017005997A2 (pt) | método | |
| EP3037523A4 (en) | Production method and cryopreservation method for amniotic mesenchymal cell composition, and therapeutic agent | |
| BR112017021191A2 (pt) | um extrato de indigo naturalis e um processo para preparar o mesmo | |
| BR112016024421A2 (pt) | composição farmacêutica, cápsula e uso da composição farmacêutica | |
| BR112015018047A8 (pt) | método para preparar composições estáveis que compreendem heparinoide, anestésico de ação aguda e tampão e as mesmas | |
| BR112015007843A2 (pt) | método para a preparação de um polímero, polímero, artigo e método de preparação de um artigo | |
| PE20170147A1 (es) | Composiciones de oligonucleotidos y metodos para realizarlas | |
| BR112015002464B8 (pt) | processo para a preparação de carbamat-benzoxazinona, carbamat-benzoxazinona e uso da carbamat-benzoxazinona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |